Table 1.
Recently published international experiences with frontline cladribine in the treatment of classic HCL
| Author | Year | Study Type | Site/Country | Patients, n | ORR | CR | Median DFS/TTF, yr | OS, % (yr) |
|---|---|---|---|---|---|---|---|---|
| Else6 | 2009 | Single center | London, UK | 45 | 100 | 76 | 11 | 100 (10) |
| Rosenberg7 | 2014 | Single center | La Jolla, CA | 83 | 100 | 88 | 5 | 80 (25) |
| Somasundaram8 | 2014 | Single center | New Delhi, India | 27 | 100 | 100 | — | — |
| Broccoli9 | 2021 | Single center | Bologna, Italy | 122 | 86 | 54 | 8 | 66 (25) |
| Ruiz-Delgado10 | 2012 | Multicenter | Mexico | 11 | 100 | 100 | — | 91 (11) |
| López Rubio11 | 2014 | Multicenter | Spain | 80 | 100 | 88 | 12 | — |
| Cornet12 | 2014 | Multicenter | France | 281 | 100 | 83 | 14 | 90 (20) |
| Hacioglu13 | 2015 | Multicenter | Turkey | 78 | 97 | 81 | 2 | 83 (19) |
| Criscuolo14 | 2019 | Multicenter | Italy | 557 | 92 | 65 | 12 | 82 (15) |
| Benz15 | 2020 | Multicenter | Switzerland | 221 | 88 | 49 | — | 67 (20) |
| Paillassa16 | 2020 | Multicenter | France | 159 | 99 | 83 | 14 | 60 (20) |
| This study | 2022 | Multicenter | Europe (4 sites) | 384 | 94 | 72 | 11 | 48 (28) |
ORR, overall response rate; TTF, time-to-treatment failure.